Home / Health / The obscure advisory committees at the heart of the U.S. drug pricing debate

The obscure advisory committees at the heart of the U.S. drug pricing debate

May 01, 2019 Health

Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries.

from Reuters: Health https://reut.rs/2IOqbZc

No comments

Subscribe to: Post Comments ( Atom )